If alerted to progressive MASLD, the diabetologist might prioritise use of glucose-lowering drugs proven effective in reversing MASH, such as glucagon-like peptide 1 (GLP-1) receptor agonists [68] and pioglitazone [69], or consider involving the bariatric surgeon. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.